CN117919331A - Application of traditional Chinese medicine composition in preparation of health food or medicine for treating chronic congestive heart failure - Google Patents
Application of traditional Chinese medicine composition in preparation of health food or medicine for treating chronic congestive heart failure Download PDFInfo
- Publication number
- CN117919331A CN117919331A CN202211256410.3A CN202211256410A CN117919331A CN 117919331 A CN117919331 A CN 117919331A CN 202211256410 A CN202211256410 A CN 202211256410A CN 117919331 A CN117919331 A CN 117919331A
- Authority
- CN
- China
- Prior art keywords
- parts
- aloe
- traditional chinese
- dry
- fructus cannabis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 28
- 206010007559 Cardiac failure congestive Diseases 0.000 title claims abstract description 21
- 230000001684 chronic effect Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title description 30
- 235000013402 health food Nutrition 0.000 title description 2
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 32
- 241001116389 Aloe Species 0.000 claims abstract description 31
- 241000167854 Bourreria succulenta Species 0.000 claims abstract description 22
- 241000612118 Samolus valerandi Species 0.000 claims abstract description 22
- 235000019693 cherries Nutrition 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 241000218236 Cannabis Species 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 239000003826 tablet Substances 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- 235000012239 silicon dioxide Nutrition 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000011812 mixed powder Substances 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229940069328 povidone Drugs 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- 239000007941 film coated tablet Substances 0.000 claims description 5
- 239000007888 film coating Substances 0.000 claims description 5
- 238000009501 film coating Methods 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 241000213006 Angelica dahurica Species 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 241000382455 Angelica sinensis Species 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000004217 heart function Effects 0.000 abstract description 7
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract description 5
- 240000004308 marijuana Species 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 25
- 238000012360 testing method Methods 0.000 description 14
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 6
- 229960004679 doxorubicin Drugs 0.000 description 6
- 230000002040 relaxant effect Effects 0.000 description 6
- 244000025254 Cannabis sativa Species 0.000 description 5
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 5
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 5
- 235000009120 camo Nutrition 0.000 description 5
- 235000005607 chanvre indien Nutrition 0.000 description 5
- 239000011487 hemp Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 241000125175 Angelica Species 0.000 description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000035611 feeding Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of a traditional Chinese medicine composition in preparing health-care food or medicine for treating chronic congestive heart failure, wherein the traditional Chinese medicine composition comprises the following raw materials: angelica sinensis, fructus cannabis, bunge cherry seed and aloe. The medicines in the traditional Chinese medicine composition play a synergistic effect after compatibility, enrich blood and nourish blood, help improve the heart function of patients with chronic heart failure, and have the efficacy of treating chronic congestive heart failure.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to an application of a traditional Chinese medicine composition in preparing health-care food or medicine for treating chronic congestive heart failure.
Background
Heart failure is a clinical syndrome in which heart diseases progress to a serious stage, also called congestive heart failure, which is a serious stage of various heart diseases and is common with chronic heart failure, due to the fact that ventricular pump blood or filling function is low, cardiac output cannot meet the metabolic demands of organisms, and tissue and organ blood is inadequately perfused, and pulmonary circulation and/or systemic circulation congestion occurs at the same time.
Chronic Congestive Heart Failure (CHF) is a clinically common disease, which occurs frequently in elderly patients, with high morbidity and mortality. The survival rate of heart failure patients in 5 years is equivalent to that of certain malignant tumors, and the hospitalization rate of hospitalized heart failure patients and the hospitalized heart failure patients in 1 year are respectively 44% and 32%. Epidemiological investigation shows that currently, the probability of CHF occurrence in people older than 65 years in China is as high as 3% -13%.
Chronic congestive heart failure is clinically a serious clinical syndrome disease with high incidence rate, and poses a great threat to the physical health and quality of life of people. Therefore, finding a positive and effective treatment for congestive heart failure has become a hot spot in recent years.
Disclosure of Invention
The invention aims to provide an application of a traditional Chinese medicine composition in preparing health-care food or medicine for treating chronic congestive heart failure.
In order to achieve the above object, the present invention provides the following technical solutions.
The application of a traditional Chinese medicine composition in preparing health-care food or medicine for treating chronic congestive heart failure comprises the following raw materials in parts by weight: 600-900 parts of Chinese angelica; 600-900 parts of fructus cannabis; 600-900 parts of bunge cherry seed; 100-150 parts of aloe.
Further, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 750-850 parts of Chinese angelica; 750-850 parts of fructus cannabis; 750-850 parts of bunge cherry seed; 115-135 parts of aloe.
Further, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 750 parts of Chinese angelica; 750 parts of fructus cannabis; 750 parts of bunge cherry seed; 125 parts of aloe.
Further, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 680 parts of Chinese angelica; 680 parts of fructus cannabis; 680 parts of bunge cherry seed; 110 parts of aloe.
Further, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 810 parts of Chinese angelica; 810 parts of fructus cannabis; 810 parts of bunge cherry seed; 145 parts of aloe.
Specifically, aloe in the raw material preferably uses whole leaf dry powder of aloe vera.
The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
a. Extracting: weighing radix Angelicae sinensis, fructus Cannabis, and semen Pruni according to formula ratio, extracting with water twice, filtering the extractive solution, and mixing filtrates;
b. concentrating: concentrating the filtrate obtained in the step a under reduced pressure to obtain extract for later use;
c. And (3) drying: c, carrying out vacuum drying on the extract obtained in the step b to obtain dry extract for later use;
d. crushing: c, crushing the dry paste obtained in the step c, and sieving to obtain dry paste powder for later use;
e. Mixing: and d, weighing the whole leaf dry powder of aloe according to the formula proportion, and uniformly mixing with the dry paste powder obtained in the step d.
Specifically, the preparation method of the traditional Chinese medicine composition comprises the following steps:
a. Extracting: weighing radix Angelicae sinensis, fructus Cannabis and semen Pruni according to formula ratio, wherein fructus Cannabis is wrapped and decocted, semen Pruni is crushed and wrapped and decocted, extracting with water twice for 1.5 hr for the first time and for 1 hr for the second time, adding water which is 8 times of the weight of the medicinal materials each time, filtering the extractive solution, and mixing filtrates;
b. concentrating: concentrating the filtrate obtained in the step a under reduced pressure until the relative density is 1.15-1.20, and performing thermal measurement at 60 ℃ to obtain extract for later use;
c. And (3) drying: c, carrying out vacuum drying on the extract obtained in the step b to obtain a dry extract for standby, and controlling the moisture of the dry extract to be less than or equal to 7.0%;
d. Crushing: c, crushing the dry paste obtained in the step c, and sieving to obtain dry paste powder for standby, wherein the mesh number of the sieve is 80;
e. Mixing: and d, weighing the whole leaf dry powder of aloe according to the formula proportion, and uniformly mixing with the dry paste powder obtained in the step d.
The traditional Chinese medicine composition can be prepared into preparations with various dosage forms according to requirements, and the preferred dosage forms are tablets, capsules, granules, powder or pills. The preparation method comprises preparing various dosage forms by conventional method and selecting appropriate adjuvants.
Furthermore, the traditional Chinese medicine composition is preferably prepared into a film coated tablet according to a conventional method.
Further, the preparation method of the film-coated tablet comprises the following steps:
a. premixing: placing the traditional Chinese medicine composition and microcrystalline cellulose with the formula amount into a mixer, and uniformly mixing to obtain mixed powder;
b. Granulating: placing the mixed powder prepared in the step a into a wet granulator, preparing a soft material by using 90% ethanol as an adhesive, sieving and granulating the soft material to obtain wet granules;
c. And (3) drying: drying the wet particles obtained in the step b to prepare dry particles;
d. Finishing: c, putting the dry particles obtained in the step c into a conical particle finishing machine for finishing, and collecting undersize particles for later use;
e. Total mixing: weighing the crosslinked povidone, the magnesium stearate and the silicon dioxide according to the formula amount, putting the crosslinked povidone, the magnesium stearate and the silicon dioxide and the granulated undersize particles into a mixer, and uniformly mixing to obtain total mixed particles;
f. Tabletting: tabletting the particles after the step e is totally mixed to obtain plain tablets for later use;
g. coating: taking a film coating premix with a formula amount, and adding water to prepare coating liquid for standby;
h. and (3) coating the plain tablet pressed in the step f by using coating liquid.
The traditional Chinese medicine composition is specially formulated for chronic congestive heart failure people according to the theory of collaterals pathology of traditional Chinese medicine under the general guiding principle that collaterals are the main and auxiliary functions. The inventor unintentionally finds that the Chinese medicinal composition prepared by mixing Chinese angelica, fructus cannabis, bunge cherry seed and aloe in the test process can improve the heart function of animals, further tries and evaluates the influence of the composition on rats with chronic heart failure, and finds that the composition has obvious effect on a doxorubicin-induced rat heart failure model.
Chronic congestive heart failure belongs to the categories of palpitation, edema and the like in traditional Chinese medicine, heart governs blood vessels, exogenous evil invasion is invading the heart, and affecting heart governs blood vessel functions leads to heart qi and heart yang deficiency, which can not promote blood circulation, and qi and blood stasis stagnation, blood stasis obstruction of collaterals, long-term blood stasis obstruction of collaterals, end body fluid and blood interchange disorder, excessive body fluid can not flow back, and edema is caused by accumulation of body fluid outside collaterals. Constipation is caused by obstruction of collaterals by blood stasis and obstruction of the intestinal tract.
In the traditional Chinese medicine composition provided by the invention, chinese angelica is a monarch drug, sweet, pungent and warm, and enters liver, heart and spleen channels, and the 'Ben Cao Zheng' records that Chinese angelica is specially used for replenishing blood and promoting blood circulation, is a qi-flowing drug in blood, and has the effects of nourishing blood and dredging collaterals. Fructus cannabis and bunge cherry seed are ministerial drugs, and fructus cannabis is sweet and flat, enters spleen, stomach and large intestine meridians, and has the effects of tonifying blood and yin, dispelling dampness and promoting urination, and relaxing bowel, and can be combined with Chinese angelica to enrich blood and nourish blood, promote urination and reduce swelling, and relax bowel. The "Ben Cao Shu" describes "Ma Zi, which is the most slippery and friendly. … … has effects of nourishing blood, nourishing yin, regulating qi and blood, eliminating pathogenic wind, and stopping sweat. For people who urinate by water conservation, the urine is slippery and descending, and water and air are led out from the urine. The bunge cherry seed is pungent, bitter, sweet and flat, enters spleen, large intestine and small intestine channels, has the effects of descending qi, promoting diuresis, relaxing bowel, and the Shennong herbal channel is called as 'main large abdomen edema, edema of faces and limbs, and urination promoting water channel', and the Chinese herbal medicine is combined with the Chinese herbal medicine, so that excessive water can flow out from urine, and simultaneously has the effect of relaxing bowel. Aloe is adjuvant drug, bitter and cold, and has effects of clearing heat and relaxing bowels. The hemp seed, the bunge cherry seed and the aloe are combined together to play roles in clearing heat and relaxing bowel, prevent constipation, treat both principal and secondary aspects of disease, effectively relieve constipation symptoms of heart failure patients, and avoid the risks of arrhythmia and the like caused by heart load increase due to constipation.
Compared with the prior art, the Chinese medicinal composition takes Chinese angelica as a monarch drug, and has the effects of replenishing blood, promoting blood circulation, nourishing blood, and dredging collaterals; fructus cannabis and bunge cherry seed are taken as ministerial drugs, and the Chinese angelica can be compatible with blood replenishing and blood nourishing, diuretic and detumescent, and intestine moistening and constipation relieving; and the aloe, the hemp seed, the bunge cherry seed and the aloe are combined together to play the roles of clearing heat and relaxing bowel. The traditional Chinese medicine composition disclosed by the invention is simple in composition and free from toxic and side effects, can effectively relieve constipation symptoms of patients with chronic congestive heart failure, reduce risks such as arrhythmia and the like, and improve symptoms and cardiac functions of patients with chronic congestive heart failure. The traditional Chinese medicine composition can be used for preparing health-care food or medicine for treating chronic congestive heart failure.
Detailed Description
The present invention will be described in further detail with reference to specific examples.
Example 1
Preparation of the composition
The formula of the raw materials comprises: 7.5kg of angelica sinensis, 7.5kg of fructus cannabis, 7.5kg of semen pruni and 1.25kg of aloe.
The preparation process comprises the following steps:
(1) Extraction of
Weighing radix Angelicae sinensis, fructus Cannabis and semen Pruni according to the formula, placing fructus Cannabis into a decoction bag, crushing semen Pruni, placing into the decoction bag, adding 180L of water, decocting for 1.5 hours, filtering, adding 180L of water into the residue again, decocting for 1 hour, filtering, and mixing the two filtrates for use.
(2) Concentrating
Concentrating the filtrate obtained in the step (1) under reduced pressure at 50-80 ℃ and 0.03-0.09 MPa to obtain extract with the relative density of 1.15-1.20 (60 ℃), and keeping the extract for later use.
(3) Drying
And (3) carrying out vacuum drying on the extract obtained in the step (2), wherein the vacuum degree is 0.04-0.10 MPa, the space temperature is 60-80 ℃, and the dry extract is obtained for standby, and the moisture of the dry extract is controlled to be less than or equal to 7.0%.
(4) Crushing
Pulverizing the dry paste obtained in the step (3) and sieving with a 80-mesh sieve to obtain dry paste powder for later use.
(5) Mixing
Weighing aloe whole leaf dry powder with a formula amount, mixing with the dry paste powder obtained in the step (4), and uniformly mixing to obtain the traditional Chinese medicine composition.
Example 2
Preparation of the composition
The formula of the raw materials comprises: 6kg of angelica, 6kg of fructus cannabis, 6kg of semen pruni and 1kg of aloe.
The preparation procedure is as in example 1.
Example 3
Preparation of the composition
The formula of the raw materials comprises: 9kg of angelica sinensis, 9kg of fructus cannabis, 9kg of semen pruni and 1.5kg of aloe.
The preparation procedure is as in example 1.
Example 4
Preparation of the composition
The formula of the raw materials comprises: 6.8kg of angelica sinensis, 6.8kg of fructus cannabis, 6.8kg of bunge cherry seed and 1.1kg of aloe whole leaf dry powder.
The preparation procedure is as in example 1.
Example 5
Preparation of the composition
The formula of the raw materials comprises: 8.1kg of angelica sinensis, 8.1kg of fructus cannabis, 8.1kg of bunge cherry seed and 1.45kg of aloe whole leaf dry powder.
The preparation procedure is as in example 1.
Example 6
Preparation of film-coated tablets of the composition
The formula comprises the following components: 0.658kg of the composition according to the invention (example 1), 0.075kg of microcrystalline cellulose, 0.035kg of crospovidone, 0.004kg of magnesium stearate, 0.004kg of silicon dioxide and 0.03kg of film coating premix.
Composition of film coating premix: titanium dioxide, talcum powder, polyethylene glycol 4000, hydroxypropyl methylcellulose, polyvinyl alcohol, lemon yellow aluminum lake and brilliant blue aluminum lake.
The preparation process comprises the following steps:
(1) Premixing
The composition of the invention prepared in the example 1 and microcrystalline cellulose with the formula amount are placed in a mixer, the rotating speed is controlled to be 8 revolutions per minute, and the mixture is mixed for 10 minutes, so as to obtain mixed powder.
(2) Granulating
Placing the mixed powder prepared in the step (1) into a wet granulator, preparing a soft material by using 90% ethanol as an adhesive, and performing swing granulation on the soft material through a 16-mesh sieve to obtain wet granules.
(3) Drying
And (3) drying the wet particles obtained in the step (2) to obtain dry particles, wherein the drying temperature is 60+/-5 ℃, and the moisture of the dry particles is controlled to be 4.0-6.0%.
(4) Finishing grain
And (3) placing the dry particles obtained in the step (3) into a conical granulator, sieving the dry particles with a 1.0mm conical sieve (about 16 meshes), and collecting undersize particles for later use.
(5) General mixing
Weighing the crosslinked povidone, magnesium stearate and silicon dioxide according to the formula amount, placing the crosslinked povidone, magnesium stearate and silicon dioxide and the granulated undersize particles into a mixer, controlling the rotating speed to 8 revolutions per minute, and mixing for 20 minutes to obtain the total mixed particles.
(6) Tabletting
And (3) putting the granules subjected to the total mixing in the step (5) into a hopper of a tablet press for tabletting, wherein the tablet weight is controlled to be 0.75 g/tablet, and the tablet weight difference is controlled to be +/-5%.
(7) Coating layer
Taking the film coating premix with the formula amount, and adding water to prepare coating liquid with the concentration of 15% for standby.
The pressed plain tablets are placed in a coating pot, the weight gain of the coating is controlled to be 4 percent, and the weight of the coated tablets is 0.78 g/tablet.
Comparative example 1
Preparation of the composition
The angelica component was reduced on the basis of example 1, and the other components were the same as in example 1.
The formula of the raw materials comprises: fructus Cannabis 7.5kg, semen Pruni 7.5kg, and Aloe 1.25kg.
The preparation procedure is as in example 1.
Comparative example 2
Preparation of the composition
The hemp seed component was reduced on the basis of example 1, and the other components were the same as in example 1.
The formula of the raw materials comprises: 7.5kg of angelica sinensis, 7.5kg of bunge cherry seed and 1.25kg of aloe.
The preparation procedure is as in example 1.
Comparative example 3
Preparation of the composition
The hemp seed was replaced with the pine nut based on example 1, and the other components were the same as in example 1.
The formula of the raw materials comprises: 7.5kg of angelica sinensis, 7.5kg of pine nut kernel, 7.5kg of bunge cherry seed kernel and 1.25kg of aloe.
The preparation procedure is as in example 1.
Comparative example 4
Preparation of the composition
The angelica is replaced by polygonum multiflorum on the basis of the embodiment 1, and other components are the same as the embodiment 1.
The formula of the raw materials comprises: 7.5kg of fleece-flower root, 7.5kg of hemp seed, 7.5kg of bunge cherry seed and 1.25kg of aloe.
The preparation procedure is as in example 1.
In order to better illustrate the characteristics of the traditional Chinese medicine composition provided by the embodiment of the invention, the traditional Chinese medicine composition prepared in the embodiment 1 and the traditional Chinese medicine compositions prepared in the comparative examples 1-4 are respectively used as test objects for testing the control effect.
The present invention will be described in further detail with reference to animal experiments.
Test examples
1. Experimental materials
1.1 Test article
The Chinese medicinal compositions prepared in example 1 and comparative examples 1 to 4 were used as test samples.
1.2 Tool drug/control drug
Doxorubicin (doxorubicin hydrochloride) 10 mg/bottle, shenzhen kaleidoscope, inc, valid period to: 2024.10 months.
1.3 A solvent: pure water.
1.4 Experimental system
1.4.1 The animal species: SD rats.
1.4.2 Animal grade: SPF stage.
1.4.3 Sex and number of animals: there were 80 total, 0 females and 80 males.
1.4.4 Age of animals: the order is about 4-6 weeks.
1.4.5 Animal body weight: ordering weight 200-220g, receiving weight 192-218 g, grouping weight 213-232g.
1.4.6 Animal certification unit, date of receipt, eligibility number: beijing Vitolihua laboratory animal technology Co., ltd., license number: SCXK (Beijing) 2021-0011, date received: 2022, 07, 13, 110011220106937037.
1.4.7 And (3) adaptive feeding: the newly received animals were kept acclimatized for 3 days. During which the animals were not abnormal in drinking, feeding and health, and no signs of illness and death were found.
1.4.8 Marks: the reference pen is numbered.
Test method
2.1 Dosage is as follows: example 1 based on a human dose of 2.74g/d, the equivalent dose is 2.74/60 x 8 = 0.4g/kg, the long-term administration is halved, and the dose is 0.2g/kg. Other comparative examples an equivalent dose efficacy comparison was performed with reference to example 1.
2.2 Grouping
Animals were divided into normal control group, model control group, example 1 group, comparative example 2 group, comparative example 3 group, comparative example 4 group according to weight balance, and specific settings are shown in table 1.
2.3 Methods of administration
The stomach 28d, 1/d.
2.4 Preparation and preservation of samples
The preparation method of the test object comprises the following steps: taking 30ml prepared in example 1 as an example, the concentration to be prepared is 0.02g powder/ml, and the sample to be weighed is: 0.6g is put into a mortar, dissolved by a proper amount of solvent and then fixed to 30ml.
Other test sample preparation refers to the method, and the volume of the prepared liquid is adjusted according to the required dosage of the test.
2.5 Administration of test substances
The corresponding test substance was withdrawn by syringe at a volume of 10ml/kg for administration.
2.6 Observed metrics, time and content
Animal modeling: 10 animals are selected for normal control, another 70 animals are established into a rat chronic heart failure model by adopting an intraperitoneal injection method of doxorubicin, the doxorubicin powder for injection is dissolved by sterilized water for injection, and the intraperitoneal injection is carried out according to the dosage of 1.5mg/kg for 2 times/week, and the total continuous injection administration is carried out for 6 weeks. The rats in the blank group were injected with an equal amount of physiological saline. After the molding is finished, the animal is subjected to heart color Doppler ultrasound examination, and the molding is successful when EF (ejection fraction) is lower than 60%. Administration was started 2 weeks after molding was successful, and after 28d total administration, 1 time/d. After the administration, the animals are subjected to conventional anesthesia, heart color Doppler ultrasound detection is carried out, and heart function indexes EF (ejection fraction), FS (short axis shortening rate of the left chamber), EDV (diastolic volume of the left chamber) and ESV (systolic volume of the left chamber) of the model animals are observed after the drug intervention.
2.7 Instrument System
DT-2000 electronic balance, double Jie instrument testing works in the well-known city of Jiangsu province.
ME104E mertler precision balance, mertler-tolido instruments (Shanghai) limited.
The small animal B ultrasonic, VEVO LAB.
2.8 Data processing
The obtained data result is usedThis means that SPSS statistical software was used for statistical testing.
Results
3.1 And (3) model: the model control animals had an EF of less than 60% compared to the normal control, suggesting that the model was successful.
3.2 Death: in the molding process, 8 animals die in total, and the other 2 animals are subjected to belly injection position burst and suppuration, which is caused by infection caused by doxorubicin or local stimulation of an injection needle, and euthanized after being removed. The remaining 60 animals were used for dosing observation.
3.3 Color Doppler ultrasound: compared with the model control group, the EF, FS, ESV, EDV of the example 1 group is obviously improved, and statistical difference (P < 0.01) is visible; the remaining comparative examples 1-4 groups showed different levels of improvement, but were significantly weaker than example 1 (P <0.05, P < 0.01) compared to example 1, and the results are shown in Table 2.
Conclusion(s)
Under the test conditions, the gastric lavage 28d of example 1 showed a significant effect on doxorubicin-induced heart failure models of rats, as evidenced by a significant improvement in heart function in the model animals. The pharmacodynamic effect of the group of example 1 is significantly better than that of the comparative group.
From the above data, the traditional Chinese medicine composition provided by the embodiment of the invention can obviously improve the heart function indexes EF (ejection fraction), FS (short axis shortening rate of left chamber), EDV (diastolic volume of left chamber) and ESV (systolic volume of left chamber) of model animals, namely is beneficial to improving the heart function of rats with chronic heart failure, and has the function of treating chronic congestive heart failure. The traditional Chinese medicine composition disclosed by the invention can be used for preparing health-care food or medicine for treating chronic congestive heart failure.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, or alternatives falling within the spirit and principles of the invention.
Claims (10)
1. The application of the traditional Chinese medicine composition in preparing health-care food or medicine for treating chronic congestive heart failure is characterized by comprising the following raw materials in parts by weight: 600-900 parts of Chinese angelica; 600-900 parts of fructus cannabis; 600-900 parts of bunge cherry seed; 100-150 parts of aloe.
2. The use according to claim 1, wherein the Chinese medicinal composition comprises the following raw materials in parts by weight: 750-850 parts of Chinese angelica; 750-850 parts of fructus cannabis; 750-850 parts of bunge cherry seed; 115-135 parts of aloe.
3. The use according to claim 1, wherein the Chinese medicinal composition comprises the following raw materials in parts by weight: 750 parts of Chinese angelica; 750 parts of fructus cannabis; 750 parts of bunge cherry seed; 125 parts of aloe.
4. The use according to claim 1, wherein the Chinese medicinal composition comprises the following raw materials in parts by weight: 680 parts of Chinese angelica; 680 parts of fructus cannabis; 680 parts of bunge cherry seed; 110 parts of aloe.
5. The use according to claim 1, wherein the Chinese medicinal composition comprises the following raw materials in parts by weight: 810 parts of Chinese angelica; 810 parts of fructus cannabis; 810 parts of bunge cherry seed; 145 parts of aloe.
6. The use according to any one of claims 1 to 5, wherein the method of preparing the traditional Chinese medicine composition comprises the steps of:
a. Extracting: weighing radix Angelicae sinensis, fructus Cannabis, and semen Pruni according to formula ratio, extracting with water twice, filtering the extractive solution, and mixing filtrates;
b. concentrating: concentrating the filtrate obtained in the step a under reduced pressure to obtain extract for later use;
c. And (3) drying: c, carrying out vacuum drying on the extract obtained in the step b to obtain dry extract for later use;
d. crushing: c, crushing the dry paste obtained in the step c, and sieving to obtain dry paste powder for later use;
e. Mixing: and d, weighing the whole leaf dry powder of aloe according to the formula proportion, and uniformly mixing with the dry paste powder obtained in the step d.
7. The use according to any one of claims 1 to 5, wherein the method of preparing the traditional Chinese medicine composition comprises the steps of:
a. Extracting: weighing radix Angelicae sinensis, fructus Cannabis and semen Pruni according to formula ratio, wherein fructus Cannabis is wrapped and decocted, semen Pruni is crushed and wrapped and decocted, extracting with water twice for 1.5 hr for the first time and for 1 hr for the second time, adding water which is 8 times of the weight of the medicinal materials each time, filtering the extractive solution, and mixing filtrates;
b. concentrating: concentrating the filtrate obtained in the step a under reduced pressure until the relative density is 1.15-1.20, and performing thermal measurement at 60 ℃ to obtain extract for later use;
c. And (3) drying: c, carrying out vacuum drying on the extract obtained in the step b to obtain a dry extract for standby, and controlling the moisture of the dry extract to be less than or equal to 7.0%;
d. Crushing: c, crushing the dry paste obtained in the step c, and sieving to obtain dry paste powder for standby, wherein the mesh number of the sieve is 80;
e. Mixing: and d, weighing the whole leaf dry powder of aloe according to the formula proportion, and uniformly mixing with the dry paste powder obtained in the step d.
8. The use according to any one of claims 1 to 5, wherein the formulation of the Chinese medicinal composition is in the form of a tablet, capsule, granule, powder or pill.
9. The use according to claim 8, wherein the tablet is a film coated tablet.
10. The use according to claim 9, wherein the method of preparing the film-coated tablet comprises:
a. premixing: placing the traditional Chinese medicine composition and microcrystalline cellulose with the formula amount into a mixer, and uniformly mixing to obtain mixed powder;
b. Granulating: placing the mixed powder prepared in the step a into a wet granulator, preparing a soft material by using 90% ethanol as an adhesive, sieving and granulating the soft material to obtain wet granules;
c. And (3) drying: drying the wet particles obtained in the step b to prepare dry particles;
d. Finishing: c, putting the dry particles obtained in the step c into a conical particle finishing machine for finishing, and collecting undersize particles for later use;
e. Total mixing: weighing the crosslinked povidone, the magnesium stearate and the silicon dioxide according to the formula amount, putting the crosslinked povidone, the magnesium stearate and the silicon dioxide and the granulated undersize particles into a mixer, and uniformly mixing to obtain total mixed particles;
f. Tabletting: tabletting the particles after the step e is totally mixed to obtain plain tablets for later use;
g. coating: taking a film coating premix with a formula amount, and adding water to prepare coating liquid for standby;
h. and (3) coating the plain tablet pressed in the step f by using coating liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211256410.3A CN117919331A (en) | 2022-10-14 | 2022-10-14 | Application of traditional Chinese medicine composition in preparation of health food or medicine for treating chronic congestive heart failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211256410.3A CN117919331A (en) | 2022-10-14 | 2022-10-14 | Application of traditional Chinese medicine composition in preparation of health food or medicine for treating chronic congestive heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117919331A true CN117919331A (en) | 2024-04-26 |
Family
ID=90749389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211256410.3A Pending CN117919331A (en) | 2022-10-14 | 2022-10-14 | Application of traditional Chinese medicine composition in preparation of health food or medicine for treating chronic congestive heart failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117919331A (en) |
-
2022
- 2022-10-14 CN CN202211256410.3A patent/CN117919331A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| WO2022036779A1 (en) | Huashibaidu granule, preparation method therefor and anti-viral drug | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| CN106362020B (en) | A kind of pine pollen composition and preparation method thereof with improvement defecating feces excretion | |
| CN102048841B (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN102188522B (en) | Traditional Chinese medicine composition for treating constipation | |
| CN117919331A (en) | Application of traditional Chinese medicine composition in preparation of health food or medicine for treating chronic congestive heart failure | |
| CN101829188B (en) | Medicament for treating urinary infection and lithiasis | |
| CN101229329A (en) | Indigestion tablet and preparing process thereof | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN104983759A (en) | Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof | |
| CN103816466A (en) | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation and preparation method thereof | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN107469014A (en) | A kind of pharmaceutical composition for treating female mammary gland proliferation disease and preparation method thereof | |
| CN113633712B (en) | Traditional Chinese medicine composition for treating gout and oral preparation based on traditional Chinese medicine composition | |
| CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis | |
| CN103191171A (en) | Natural medicine for treating 2 type diabetes, and preparation method thereof | |
| CN106138194A (en) | A kind of compound Chinese medicinal preparation treating hyperuricemia and preparation method thereof | |
| CN104352862A (en) | Emblic leafflower fruit-containing traditional Chinese medicine composition for treating diabetes | |
| CN116098960A (en) | Traditional Chinese medicine composition for treating chronic heart failure as well as preparation method and application thereof | |
| CN105250749A (en) | Traditional Chinese medicine for treating thyroid adenoma and preparation method thereof | |
| CN104208126A (en) | New formula for preventing and treating nephrosis syndrome and preparation method thereof | |
| CN117919346A (en) | Medicinal and edible traditional Chinese medicine compound for treating hyperuricemia and gouty arthritis and application thereof | |
| CN104027450A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN114984179A (en) | Composition for treating or preventing mitiglinide adverse reaction and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |